Table 1.

Summary of emerging systemic AD therapies

Drug	Target	Administration route	Dosage	Most frequent TEAEs	Clinical trial phasea
Dupilumab	IL-4Rα	Subcutaneous	600 mg LD followed by 300 mg every 2 weeks OR 400 mg LD followed by 200 mg every 2 weeksb OR 300 mg followed by 300 mg after 2 weeks, then 300 mg every 4 weeksc	Conjunctivitis, oral herpes simplex virus reactivation, arthralgia, eosinophilia, injection site reactions	IV
Lebrikizumab	IL-13	Subcutaneous	500 mg LD followed by 250 mg every 2 or 4 weeks OR 250 mg LD followed by 125 mg every 4 weeks	URTI, nasopharyngitis, headache, fatigue, injection site reactions	III
Tralokinumab	IL-13	Subcutaneous	600 mg LD followed by 300 mg every 2 weeks	Viral URTI, URTI, conjunctivitis	III
Nemolizumab	IL-31Rα	Subcutaneous	60 mg every 4 weeks OR 60 mg LD followed by 30 mg every 4 weeks	Nasopharyngitis, URTI, blood levels of CPK increased, urticaria, acne	III
Upadacitinib	JAK-1	Oral	30 mg or 15 mg once daily	URTI, acne, herpes simplex virus reactivation, headache, blood levels of CPK increased, cough, folliculitis	IV
Baricitinib	JAK-1/JAK-2	Oral	4 mg or 2 mg once daily	Headache, blood levels of CPK increased, URTI, nasopharyngitis	III
Abrocitinib	JAK-1	Oral	200 mg or 100 mg once daily	Nausea, nasopharyngitis, headache, URTI, herpes simplex, or herpes zoster virus reactivation	IV
GBR 830	OX40	Intravenous	10 mg/kg every 2 weeks	Pyrexia, chills, aphthous ulcer, blood uric acid increased, nasopharyngitis, erythema, hordeolum	II

TEAEs treatment-emergent adverse events, LD loading dose, URTI upper respiratory tract infection, CPK creatine phosphokinase

^aClinical trials available at clinicaltrials.gov as of November 18, 2022

^bIn adolescent patients 12–17 years of age with a body weight of less than 60 kg

^cIn children 6–11 years of age with a body weight of 15 to less than 60 kg